Photo by nci from unsplash
decreased lymphoma‐specific mortality, adjusted HR 0.09 (0.01, 0.64). Further dose‐response analyses are planned. Conclusions: In this very large population‐based unselected lymphoma population, statins were not associated with worse outcomes and… Click to show full abstract
decreased lymphoma‐specific mortality, adjusted HR 0.09 (0.01, 0.64). Further dose‐response analyses are planned. Conclusions: In this very large population‐based unselected lymphoma population, statins were not associated with worse outcomes and thus appear safe to use during lymphoma treatment. Interestingly, Burkitt patients using statins had a statistically significant decreased lymphoma‐specific mortality.
Keywords:
pharmacokinetic results;
exposure rituximab;
ibrutinib increases;
increases systemic;
systemic exposure;
rituximab pharmacokinetic
Journal Title: Hematological Oncology
Year Published: 2017
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!
Journal Title: Hematological Oncology
Year Published: 2017
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!